Immunosignatures associated with TP53 status and co-mutations classify prognostically head and neck cancer patients

BACKGROUND: Immune checkpoint inhibitors (ICIs) are a therapeutic strategy for various cancers although only a subset of patients respond to the therapy. Identifying patients more prone to respond to ICIs may increase the therapeutic benefit and allow studying new approaches for resistant patients....

Descripción completa

Detalles Bibliográficos
Autores principales: Sacconi, Andrea, Muti, Paola, Pulito, Claudio, Urbani, Giulia, Allegretti, Matteo, Pellini, Raul, Mehterov, Nikolay, Ben-David, Uri, Strano, Sabrina, Bossi, Paolo, Blandino, Giovanni
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Correspondence
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687972/
https://www.ncbi.nlm.nih.gov/pubmed/38031025
http://dx.doi.org/10.1186/s12943-023-01905-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10687972/
https://www.ncbi.nlm.nih.gov/pubmed/38031025
http://dx.doi.org/10.1186/s12943-023-01905-9

Ejemplares similares